Table 5.

Effect of change in averaged urine potassium (UKE) and creatinine (UCreat) excretions on ADPKD progression in Study B^&

(A) Of averaged UKE on change in hazard ratio for combined endpoint of death, ESRD or 50% reduction in   eGFR
Effect	p-value	Hazard Ratio	Lower	Upper
ACE-I + ARB	0.735	0.947	0.692	1.296
Averaged UKE (per 6mEq/24hr)‡	0.023	0.932	0.944	0.995
(B) Of averaged UKE on annual eGFR slope (ml/min/1.73 m2/yr)
Effect	p-value	Estimate	Lower	Upper
Year	<0.001	−3.303	−3.655	−2.950
Year*ACE-I + ARB	0.836	0.020	−0.170	0.210
Averaged UKE (per 6mEq/24hr)‡	0.419	0.013	−0.019	0.045
Year*Averaged UKE (per 6mEq/24hr)‡	0.009	0.588	0.144	1.031
(C) Of averaged UCreat on change in hazard ratio for combined endpoint of death, ESRD or 50% reduction   in eGFR
Effect	P-value	Hazard Ratio	Lower	Upper
ACE-I + ARB	0.712	0.943	0.691	1.288
Averaged UCreat (per 150mg/24hr)‡	0.346	0.957	0.937	1.000
(D) Of averaged UCreat on annual eGFR slope (ml/min/1.73 m2/yr)
Effect	P-value	Estimate	Lower	Upper
Year	<0.001	−2.774	−3.109	−2.438
Year*ACE-I + ARB	0.873	0.016	−0.174	0.205
Averaged UCreat (per 150mg/24hr)‡	0.081	0.570	−0.070	1.211
Year*Averaged UCreat (per 150mg/24hr)‡	0.012	−0.044	−0.079	−0.010

^&All models adjusted for the following covariates: age, race, gender, and body surface area (BSA)

^‡Averaged UKE and UCreat from 4 month visit (F5) to the end of the study (F96)